Related Experiment Video
Updated: May 19, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Antihyperglycemic agents from Ammannia multiflora.
Harish C Upadhyay1, Natasha Jaiswal, Akhilesh K Tamrakar
1Medicinal Chemistry Department,Central Institute of Medicinal and Aromatic Plants, Lucknow-226015, India.
Natural Product Communications
|August 23, 2012
Summary
Ammannia multiflora yielded compounds with antihyperglycemic properties. A derivative, 1D, significantly boosted glucose uptake, showing potential as a new herbal antidiabetic drug.
Area of Science:
- Phytochemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Diabetes mellitus is a global health concern requiring novel therapeutic agents.
- Herbal medicines offer a rich source of potential antidiabetic compounds.
- Ammannia multiflora is a plant with traditional medicinal uses.
Purpose of the Study:
- To isolate and characterize bioactive compounds from Ammannia multiflora.
- To evaluate the antihyperglycemic activity of isolated compounds and their derivatives.
- To identify potential new antidiabetic drug candidates from natural sources.
Main Methods:
- Serial chromatographic separation of plant extracts.
- Chemical modification of isolated compounds to synthesize derivatives.
- In vitro evaluation of antihyperglycemic activity using 2-deoxyglucose uptake assay in L-6 rat muscle cells.
Main Results:
- Isolation of 4-hydroxy-alpha-tetralone (1) and ammaniol (2).
- Synthesis of six semi-synthetic derivatives (1A-1F) of compound 1.
- Both isolates and derivatives demonstrated glucose uptake stimulation.
- Ammaniol (2) increased glucose uptake by 64.8%.
- Derivative 1D showed potent antihyperglycemic activity, increasing glucose uptake by 94.6%, exceeding rosiglitazone (88.8%).
Conclusions:
- Ammannia multiflora contains compounds with significant antihyperglycemic potential.
- Semi-synthetic derivative 1D exhibits superior in vitro antihyperglycemic activity compared to the standard drug rosiglitazone.
- Compound 1D represents a promising lead for the development of a novel, safer antidiabetic drug of herbal origin.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...